Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 2, Pages 231
Publisher
MDPI AG
Online
2021-01-11
DOI
10.3390/cancers13020231
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New predictors for immunotherapy responses sharpen our view of the tumour microenvironment
- (2020) Tullia C. Bruno NATURE
- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma
- (2020) Rita Cabrita et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis
- (2020) Suguru Kadomoto et al. Cancers
- Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.
- (2020) Miriam Ficial et al. JOURNAL OF CLINICAL ONCOLOGY
- BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
- (2020) Nicolas Epaillard et al. BULLETIN DU CANCER
- LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
- (2020) Y. Vano et al. ANNALS OF ONCOLOGY
- The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
- (2019) Charlotte M. Huijts et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
- (2019) Jean-Christophe Pignon et al. CLINICAL CANCER RESEARCH
- Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial
- (2019) A. Ari Hakimi et al. Cancer Discovery
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) Bernard Escudier et al. ANNALS OF ONCOLOGY
- Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors
- (2019) Annelies Verbiest et al. Clinical Genitourinary Cancer
- Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
- (2019) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- The influence of microenvironment on tumor immunotherapy
- (2019) Jieying Zhang et al. FEBS Journal
- Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry
- (2019) Valeria Ramaglia et al. eLife
- Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy
- (2019) Isabel Heidegger et al. Frontiers in Oncology
- Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
- (2019) Tianyi Liu et al. Frontiers in Cell and Developmental Biology
- Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells
- (2019) Charles-Antoine Dutertre et al. IMMUNITY
- The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results
- (2019) Ismail Selvi et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma
- (2019) Philipp J. Stenzel et al. Translational Oncology
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens
- (2018) Jeff DeFalco et al. CLINICAL IMMUNOLOGY
- Enduring epigenetic landmarks define the cancer microenvironment
- (2018) Ruth Pidsley et al. GENOME RESEARCH
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment
- (2018) Sundary Sormendi et al. Frontiers in Immunology
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).
- (2018) Martin Henner Voss et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
- (2018) B I Rini et al. ANNALS OF ONCOLOGY
- Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness
- (2017) Daniel J. Serie et al. EUROPEAN UROLOGY
- Anti-VEGFR, PDGFR, and CSF1R tyrosine kinase inhibitor CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma: a phase 1 clinical trial
- (2017) Xieqiao Yan et al. LANCET ONCOLOGY
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Human renal adipose tissue induces the invasion and progression of renal cell carcinoma
- (2017) Fiorella Campo-Verde-Arbocco et al. Oncotarget
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
- (2017) Pornpimol Charoentong et al. Cell Reports
- Transforming growth factor β as regulator of cancer stemness and metastasis
- (2016) Claudia Bellomo et al. BRITISH JOURNAL OF CANCER
- Tim-3 Expression on Tumor-Infiltrating PD-1 + CD8 + T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
- (2016) Clémence Granier et al. CANCER RESEARCH
- Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α
- (2016) Yana G. Najjar et al. CLINICAL CANCER RESEARCH
- Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma
- (2016) José I. López et al. HUMAN PATHOLOGY
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
- (2016) Naomi B Haas et al. LANCET
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
- (2016) Alain Ravaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5
- (2016) Vittoria D'Esposito et al. Oncotarget
- Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance
- (2016) Susana Romero-Garcia et al. Frontiers in Immunology
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- Regulatory B Cells: Origin, Phenotype, and Function
- (2015) Elizabeth C. Rosser et al. IMMUNITY
- Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma
- (2015) Shlomi Finkin et al. NATURE IMMUNOLOGY
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- (2015) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma
- (2015) Zipei Feng et al. Journal for ImmunoTherapy of Cancer
- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
- (2014) Edward C. Stack et al. METHODS
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
- (2014) Marco Gerlinger et al. NATURE GENETICS
- Tertiary lymphoid structures in cancer and beyond
- (2014) Marie-Caroline Dieu-Nosjean et al. TRENDS IN IMMUNOLOGY
- Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma
- (2013) Matteo Santoni et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- B cells and their mediators as targets for therapy in solid tumors
- (2013) Andrew J. Gunderson et al. EXPERIMENTAL CELL RESEARCH
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Macrophage biology in development, homeostasis and disease
- (2013) Thomas A. Wynn et al. NATURE
- Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
- (2013) Je-In Youn et al. NATURE IMMUNOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-associated macrophages: functional diversity, clinical significance, and open questions
- (2013) Subhra K. Biswas et al. Seminars in Immunopathology
- Molecular signatures from omics data: From chaos to consensus
- (2012) Jaeyun Sung et al. Biotechnology Journal
- Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology
- (2012) Claudia A. Dumitru et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Associated Macrophages Mediate Immunosuppression in the Renal Cancer Microenvironment by Activating the 15-Lipoxygenase-2 Pathway
- (2011) I. Daurkin et al. CANCER RESEARCH
- Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer
- (2011) M Kawada et al. ONCOGENE
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast
- (2010) M Bauer et al. ONCOGENE
- Autocrine TGF- and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts
- (2010) Y. Kojima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Cancer-associated fibroblasts and tumor growth – bystanders turning into key players
- (2009) Arne Östman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started